1. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S–93S.
2. Piert M, Machulla H-J, Picchio M, Reischl G, Ziegler S, Kumar P, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005;46:106–13.
3. Beer AJ, Haubner R, Goebel M, Luderschmidt S, Spilker ME, Wester HJ, et al. Biodistribution and pharmacokinetics of the {alpha}v{beta}3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 2005;46:1333–41.
4. Picchio M, Treiber U, Beer AJ, Metz S, Bossner P, van Randenborgh H, et al. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings. J Nucl Med 2006;47:938–44.
5. Yamamoto S, Matsumoto K, Senda M. Optimum threshold setting for a positron-sensitive probe with background rejection capability. Ann Nucl Med 2004;18:251–6.